METTL3 and hepatocellular carcinoma: Interestingly, silencing METTL3 or treating HCC cells with the METTL3 inhibitor STM2457 resulted in a significant reduction in the binding of IGF2BP3 to circRAPGEF1(Figure 4H), accompanied by a decrease in circRAPGEF1 expression and stability (Figure 4I,J).